Loading
companiesCompany
Tango Therapeutics
Tango Therapeutics makes cancer pills that exploit a weakness created when a tumour loses a particular gene. Its lead drug targets cancers that have lost a gene called MTAP, common in pancreatic and lung cancer.
Overview
Tango Therapeutics is a Boston precision oncology company built on synthetic lethality: it uses CRISPR-based functional genomic screens to find targets that cancer cells depend on once they have lost a tumour suppressor gene. Its lead programme, vopimetostat (TNG462), is an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, listed in phase 1/2 and phase 3 development in pancreatic, lung and other non-CNS cancers, with a phase 1/2 combination study alongside Revolution Medicines' RAS inhibitors. TNG456, a brain-penetrant PRMT5 inhibitor, is in phase 1/2 for MTAP-deleted glioblastoma. All programmes are wholly owned. Tango listed on Nasdaq in August 2021 through a merger with BCTG Acquisition Corp, a SPAC sponsored by Boxer Capital, with a 186 million US dollar PIPE and about 353 million US dollars in expected total proceeds; Gilead Sciences was an existing shareholder.
Headquarters
Boston, MA, US
Scorecard
All companies#358of 1244 companies, score 11
- phase 1/2 +3
- targets +2
- modalities +2
- registry trials +4
0 approved, 0 in phase 3, 3 earlier, 1 targets, 5 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · Nasdaq listing via merger with BCTG Acquisition Corp; approximately 353 million US dollars expected gross proceeds (about 167 million in trust plus a 186 million PIPE led by Boxer Capital), before redemptions | 2021 | $353M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · TNGX
Stage
Public
Website
Phase 2small molecule
TNG462 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).
Phase 2small molecule
TNG456 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for non-small-cell lung cancer and glioma & glioblastoma, aimed at PRMT5 (MTAP-deleted cancers).
Phase 2Small-molecule inhibitor
TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
Notes
top- Founding year (2017) not sourced from a fetched page. Final proceeds after redemptions were not confirmed; the 353 million figure is the expected total stated in the announcement.
Similar pages
- CompanyObsidian Therapeutics
Shares Logos Capital, Foresite Capital, RA Capital Management, Non-small-cell lung cancer.
- TargetPRMT5 (MTAP-deleted cancers)
Shares TNG456, TNG462, Synthetic lethality approaches, Glioma & glioblastoma.
- CompanyTriana Biomedicines
Shares Logos Capital, RA Capital Management, Non-small-cell lung cancer.
- CompanyAlpha-9 Oncology
Shares Samsara BioCapital, RA Capital Management.
- CompanyBridgeBio Oncology Therapeutics
Shares Cormorant Asset Management, Non-small-cell lung cancer.
- CompanyBlack Diamond Therapeutics
Shares Casdin Capital, Glioma & glioblastoma, Non-small-cell lung cancer.
- IdeaMake bespoke mouse cancer models in weeks with in vivo gene editing
Shares CRISPR functional genomics, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- CompanyRevolution Medicines
Shares Boxer Capital, Bain Capital Life Sciences, Pancreatic ductal adenocarcinoma.
cancers
fronts
technologies
drugs
companies
trials
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPSafety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossSafety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsStudy of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients